Clinical impact of preemptive pharmacogenomic testing on antiplatelet therapy in a real-world setting

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Clinical Trial Design

Background:

• CYP2C19 genotyping guides antiplatelet therapy post-acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), reducing major adverse cardiovascular events (MACE).
• Limited evidence exists on the impact of preemptive CYP2C19 genotyping, performed before a clinical need arises.

Purpose of the Study:

• To compare the effects of preemptive, early, and late CYP2C19 genotyping on antiplatelet selection and patient outcomes.
• To evaluate the influence of genotyping timing on medication choices, healthcare utilization, and clinical events over one year.

Main Methods:

• Retrospective analysis of medical records from 200 patients undergoing antiplatelet therapy for ACS or PCI.
• Comparison of three groups: preemptive genotyping (>7 days before need), early genotyping (within 7 days of need), and late genotyping (>7 days after need).
• Propensity score matching was used to balance patient characteristics between the preemptive and early genotyping groups.

Main Results:

• Patients with CYP2C19 loss-of-function alleles were less likely to receive clopidogrel with preemptive genotyping (18.2%) compared to early (66.7%) or late (73.2%) genotyping (P=.001).
• No significant differences were observed in specialty visits, MACE, or bleeding events across the genotyping timing groups (P>.21).

Conclusions:

• Preemptive CYP2C19 genotyping substantially influences initial antiplatelet medication selection in patients with ACS or undergoing PCI.
• The timing of CYP2C19 genotyping did not impact patient outcomes (MACE, bleeding) or healthcare utilization within one year.